Document Detail

Morphea associated with the use of adalimumab: a case report and review of the literature.
MedLine Citation:
PMID:  22095405     Owner:  NLM     Status:  MEDLINE    
Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment.
Julio Ramírez; M Victoria Hernández; Javier Galve; Juan D Cañete; Raimon Sanmartí
Related Documents :
3050815 - Asymptomatic innominate vein tamponade with retromanubrial clavicular dislocation. a ca...
353625 - Traumatic herniation of buccal pad of fat (traumatic pseudolipoma). a review.
20607215 - Brachial artery transection caused by closed elbow dislocation in a mature in-line skat...
2645935 - Ganglion of the temporomandibular joint. case report and literature survey.
17364095 - Use of transilial pinning for the treatment of sacroiliac separation in 25 dogs and fin...
6139955 - Multiple endocrine neoplasia, type 2b, as a cause of megacolon.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2011-11-18
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  22     ISSN:  1439-7609     ISO Abbreviation:  Mod Rheumatol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-13     Completed Date:  2013-01-08     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  602-4     Citation Subset:  IM    
Arthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / adverse effects*
Antirheumatic Agents / adverse effects*
Lower Extremity
Scleroderma, Localized / chemically induced*,  diagnosis
Skin / drug effects,  pathology
Spondylitis, Ankylosing / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Withholding Treatment
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ER Stress, P66shc, and P-Akt/Akt Mediate Adjuvant-Induced Inflammation, Which Is Blunted by Argirein...
Next Document:  Extraction of lignins from aqueous-ionic liquid mixtures by organic solvents.